Evidence map›Paper›PMID 41437962›Full record

ArticleInternational journal of particle therapy2025

"Hadrontherapy for Life" Symposium, Caen, March 10/11, 2025-Strategy for the Future-Pediatric Tumors.

Jean-Louis Habrand, Semi B Harrabi, Shigeru Yamada, Zheng Wang, Siamak Haghdoost, Ellie Light, Tatsuya Ohno, Jerôme Doyen, Remi Dendale, Jacques Balosso and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jean-Louis HabrandRadiation Oncology Department, François Baclesse Cancer Center, Caen, France.
Semi B HarrabiRadiation Oncology Department, Heidelberg University Hospital, Heidelberg, Germany.
Shigeru YamadaQST Hospital, National Institutes of Quantum and Radiological Science and Technology, Chiba, Japan.
Zheng WangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Siamak HaghdoostABTE/ToxEMAC Laboratory, University of Caen Normandy, Caen, France.
Ellie LightRadiotherapy Department, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Tatsuya OhnoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Jerôme DoyenRadiation Oncology Department, Antoine Lacassagne Cancer Center, Nice, France.
Remi DendaleRadiation Oncology Department, Institut Curie, Paris, France.
Jacques BalossoRadiation Oncology Department, Grenoble University Hospital, Grenoble, France.
Audrey LarnaudieRadiation Oncology Department, François Baclesse Cancer Center, Caen, France.
Anthony VelaRadiation Oncology Department, François Baclesse Cancer Center, Caen, France.
Arnold PomposRadiation Oncology Department, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bradford HoppeRadiation Oncology Department, Mayo Clinic Florida, Jacksonville, FL, USA.
Anita MahajanRadiation Oncology Department, Mayo Clinic Rochester, Rochester, MN, USA.
Juliette ThariatRadiation Oncology Department, François Baclesse Cancer Center, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symposium "Hadrontherapy for life," held in Caen, on March 10 and 11, 2025, brought together over 100 international experts of heavy ions particle therapy. Clinical aspects of current indications and future strategies were discussed. If protontherapy remains the cornerstone of current strategies dealing with pediatric malignancies, in order to better spare normal tissues from deleterious effects of radiation, heavier ions such as carbon ions could play a role in selected highly radio-resistant processes such as bone and non rhabdomyosrcomas soft tissue sarcomas. A special mention should be made to helium ions tested since 2021 in Europe that mimic protons with further ballistic selectivity. If immediate and early side effects of heavy ions look modest, long-term tolerance still needs to be carefully evaluated, including risks of carcinogenesis.

Indexed as

Heavy ion therapyOsteosarcomaPediatric tumors

Identifiers

PMID41437962
PMCPMC12721058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.